Therefore, another signaling pathway model was proposed by the authors, suggesting that the miR-203a/Bmi1/p-Akt axis might participate in the development of cholesteatoma and become a future target in pharmacological treatment [68]. This evidence concerns the gene AKT1 and cholesteatoma.